FARON PHARMACEUTICALS OY — Director's Dealing 2026

Jan 13, 2026

National Storage Mechanism | Additional information

Faron Pharmaceuticals

13 Jan 2026 16:00 UTC

---

Faron Pharmaceuticals Ltd: PDMR Dealing

Faron Pharmaceuticals Ltd | Company announcement | January 13, 2026 at 18:00:00 EET

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Mr. Jurriaan Dekkers, Chief Financial Officer of the Company, sold 4,000 ordinary shares in Faron at price of £1.822 per share on 12 January 2026.

Further details are set out in the Notification of Dealing Form below.

PDMR	Holding prior to sale	Number of ordinary shares sold	Resultant interest in ordinary shares in the Company	Resultant percentage of voting rights in the Company
Jurriaan Dekkers	4,000	4,000	0	0.0%

For more information, please contact:

IR Partners, Finland**(Media)**Kare Laukkanen	+358 50 553 9535 / +44 7 469 766 223**[email protected]**
FINN Partners, US**(Media)** Alyssa Paldo	+1 847 791-8085 [email protected]
Cairn Financial Advisers LLP**(Nominated Adviser and Broker)**Sandy Jamieson, Jo Turner	+44 (0) 207 213 0880
Sisu Partners Oy**(Certified Adviser on Nasdaq First North)Juha KarttunenJukka Järvelä**	+358 (0)40 555 4727**+358 (0)50 553 8990**

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Jurriaan Dekkers
2	Reason for notification
a.	Position/Status	Chief Financial Officer
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Faron Pharmaceuticals Ltd.
b.	LEI	7437009H31TO1DC0EB42
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares ISIN: FI4000153309
b.	Nature of the transaction	Sale of Ordinary Shares
			Price(s) per share (p)	Volume(s)
£1.822	4,000
d.	Aggregated information Volume Price	4,000 £1.822
e.	Date of the transaction	12/01/2026
f.	Place of the transaction	London Stock Exchange, AIM

---

MFN is a regulatory news distribution service and it is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. The service is built to easily manage all the tasks of news distribution for listed companies.

For further information, please contact [email protected] or visit Modular Finance.

View the source version on MFN: Faron Pharmaceuticals Ltd: PDMR Dealing